This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Health Winners & Losers: ImClone

The Nasdaq and Amex biotech indices were down 2.2% and 2.6%, respectively.

The Wall Street Journal reported late Wednesday that Eli Lilly (LLY) is ImClone's (IMCL) mystery bidder. Later Wednesday, ImClone Chairman Carl Icahn said in a release that the mystery suitor made a proposal not subject to financing or further due diligence. Negotiations are reportedly under way and the company has requested that ImClone not reveal the bidder's name until negotiations are complete.

ImClone shares were trading up 35 cents, or 0.5%, at $65.70. Eli Lilly shares were down 30 cents, or 0.7%, at $43.39.

Shares of Bristol Myers Squibb (BMY), which last week announced a hostile tender for ImClone at $62 a share, were down 10 cents, or 0.5%, at $20.69.

In other big biotech merger news, Roche reaffirmed that it's committed to a deal with Genentech (DNA). Investor skepticism about the financing of the proposed $89 a share buyout has recently depressed the share price. Shares were up 20 cents, or 0.2%, at $86.70 in recent trading Thursday.

In pharma news, Merck (MRK) said Thursday that it is discontinuing the late-stage clinical development program for taranabant for obesity and will not seek regulatory approval for the drug in that indication. The company said that available phase III data showed that both efficacy and adverse events were dose related, with greater efficacy and more adverse events in the higher doses.

Lazard analysts said it was no surprise as the safety and efficacy from taranabant's drug class, which includes Sanofi Aventis' Zimulti, for example, have disappointed. Merck's shares were off by 25 cents, or 0.8%, at $31.84.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,172.68 -107.06 -0.62%
S&P 500 1,994.29 -16.11 -0.80%
NASDAQ 4,527.6890 -52.10 -1.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs